Rationale, design, and development of SleepWell24: A smartphone application to promote adherence to positive airway pressure therapy among patients with obstructive sleep apnea

Megan E. Petrov, Kristina Hasanaj, Coles M. Hoffmann, Dana R. Epstein, Lois Krahn, John G. Park, Kevin Hollingshead, Tsung Yen Yu, Michael Todd, Erik K. St. Louis, Timothy I. Morgenthaler, Matthew P. Buman

Research output: Contribution to journalArticle

Abstract

Background: Positive airway pressure (PAP) therapy is the gold standard treatment for obstructive sleep apnea (OSA), a chronic disorder that affects 6–13% of the adult population. However, adherence to PAP therapy is challenging, and current approaches to improve adherence have limited efficacy and scalability. Methods/design: To promote PAP adherence, we developed SleepWell24, a multicomponent, evidence-based smartphone application that delivers objective biofeedback concerning PAP use and sleep/physical activity patterns via cloud-based PAP machine and wearable sensor data, and behavior change strategies and troubleshooting of PAP therapy interface use. This randomized controlled trial will evaluate the feasibility, acceptability, and initial efficacy of SleepWell24 compared to a usual care control condition during the first 60 days of PAP therapy among patients newly diagnosed with OSA. Discussion: SleepWell24 is an innovative, multi-component behavior change intervention, designed as a self-management approach to addressing the psychosocial determinants of adherence to PAP therapy among new users. The results will guide lengthier future trials that assess numerous patient-centered and clinical outcomes.

Original languageEnglish (US)
Article number105908
JournalContemporary Clinical Trials
Volume89
DOIs
StatePublished - Feb 2020

Fingerprint

Obstructive Sleep Apnea
Pressure
Therapeutics
Smartphone
Self Care
Sleep
Randomized Controlled Trials
Exercise
Population

Keywords

  • Mobile health
  • Obstructive sleep apnea
  • Physical activity
  • Sleep
  • Wearable sensors

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Rationale, design, and development of SleepWell24 : A smartphone application to promote adherence to positive airway pressure therapy among patients with obstructive sleep apnea. / Petrov, Megan E.; Hasanaj, Kristina; Hoffmann, Coles M.; Epstein, Dana R.; Krahn, Lois; Park, John G.; Hollingshead, Kevin; Yu, Tsung Yen; Todd, Michael; St. Louis, Erik K.; Morgenthaler, Timothy I.; Buman, Matthew P.

In: Contemporary Clinical Trials, Vol. 89, 105908, 02.2020.

Research output: Contribution to journalArticle

Petrov, Megan E. ; Hasanaj, Kristina ; Hoffmann, Coles M. ; Epstein, Dana R. ; Krahn, Lois ; Park, John G. ; Hollingshead, Kevin ; Yu, Tsung Yen ; Todd, Michael ; St. Louis, Erik K. ; Morgenthaler, Timothy I. ; Buman, Matthew P. / Rationale, design, and development of SleepWell24 : A smartphone application to promote adherence to positive airway pressure therapy among patients with obstructive sleep apnea. In: Contemporary Clinical Trials. 2020 ; Vol. 89.
@article{1a4b6ff1b1ea410abe789aa5f4d2adb9,
title = "Rationale, design, and development of SleepWell24: A smartphone application to promote adherence to positive airway pressure therapy among patients with obstructive sleep apnea",
abstract = "Background: Positive airway pressure (PAP) therapy is the gold standard treatment for obstructive sleep apnea (OSA), a chronic disorder that affects 6–13{\%} of the adult population. However, adherence to PAP therapy is challenging, and current approaches to improve adherence have limited efficacy and scalability. Methods/design: To promote PAP adherence, we developed SleepWell24, a multicomponent, evidence-based smartphone application that delivers objective biofeedback concerning PAP use and sleep/physical activity patterns via cloud-based PAP machine and wearable sensor data, and behavior change strategies and troubleshooting of PAP therapy interface use. This randomized controlled trial will evaluate the feasibility, acceptability, and initial efficacy of SleepWell24 compared to a usual care control condition during the first 60 days of PAP therapy among patients newly diagnosed with OSA. Discussion: SleepWell24 is an innovative, multi-component behavior change intervention, designed as a self-management approach to addressing the psychosocial determinants of adherence to PAP therapy among new users. The results will guide lengthier future trials that assess numerous patient-centered and clinical outcomes.",
keywords = "Mobile health, Obstructive sleep apnea, Physical activity, Sleep, Wearable sensors",
author = "Petrov, {Megan E.} and Kristina Hasanaj and Hoffmann, {Coles M.} and Epstein, {Dana R.} and Lois Krahn and Park, {John G.} and Kevin Hollingshead and Yu, {Tsung Yen} and Michael Todd and {St. Louis}, {Erik K.} and Morgenthaler, {Timothy I.} and Buman, {Matthew P.}",
year = "2020",
month = "2",
doi = "10.1016/j.cct.2019.105908",
language = "English (US)",
volume = "89",
journal = "Contemporary Clinical Trials",
issn = "1551-7144",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Rationale, design, and development of SleepWell24

T2 - A smartphone application to promote adherence to positive airway pressure therapy among patients with obstructive sleep apnea

AU - Petrov, Megan E.

AU - Hasanaj, Kristina

AU - Hoffmann, Coles M.

AU - Epstein, Dana R.

AU - Krahn, Lois

AU - Park, John G.

AU - Hollingshead, Kevin

AU - Yu, Tsung Yen

AU - Todd, Michael

AU - St. Louis, Erik K.

AU - Morgenthaler, Timothy I.

AU - Buman, Matthew P.

PY - 2020/2

Y1 - 2020/2

N2 - Background: Positive airway pressure (PAP) therapy is the gold standard treatment for obstructive sleep apnea (OSA), a chronic disorder that affects 6–13% of the adult population. However, adherence to PAP therapy is challenging, and current approaches to improve adherence have limited efficacy and scalability. Methods/design: To promote PAP adherence, we developed SleepWell24, a multicomponent, evidence-based smartphone application that delivers objective biofeedback concerning PAP use and sleep/physical activity patterns via cloud-based PAP machine and wearable sensor data, and behavior change strategies and troubleshooting of PAP therapy interface use. This randomized controlled trial will evaluate the feasibility, acceptability, and initial efficacy of SleepWell24 compared to a usual care control condition during the first 60 days of PAP therapy among patients newly diagnosed with OSA. Discussion: SleepWell24 is an innovative, multi-component behavior change intervention, designed as a self-management approach to addressing the psychosocial determinants of adherence to PAP therapy among new users. The results will guide lengthier future trials that assess numerous patient-centered and clinical outcomes.

AB - Background: Positive airway pressure (PAP) therapy is the gold standard treatment for obstructive sleep apnea (OSA), a chronic disorder that affects 6–13% of the adult population. However, adherence to PAP therapy is challenging, and current approaches to improve adherence have limited efficacy and scalability. Methods/design: To promote PAP adherence, we developed SleepWell24, a multicomponent, evidence-based smartphone application that delivers objective biofeedback concerning PAP use and sleep/physical activity patterns via cloud-based PAP machine and wearable sensor data, and behavior change strategies and troubleshooting of PAP therapy interface use. This randomized controlled trial will evaluate the feasibility, acceptability, and initial efficacy of SleepWell24 compared to a usual care control condition during the first 60 days of PAP therapy among patients newly diagnosed with OSA. Discussion: SleepWell24 is an innovative, multi-component behavior change intervention, designed as a self-management approach to addressing the psychosocial determinants of adherence to PAP therapy among new users. The results will guide lengthier future trials that assess numerous patient-centered and clinical outcomes.

KW - Mobile health

KW - Obstructive sleep apnea

KW - Physical activity

KW - Sleep

KW - Wearable sensors

UR - http://www.scopus.com/inward/record.url?scp=85076776215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076776215&partnerID=8YFLogxK

U2 - 10.1016/j.cct.2019.105908

DO - 10.1016/j.cct.2019.105908

M3 - Article

AN - SCOPUS:85076776215

VL - 89

JO - Contemporary Clinical Trials

JF - Contemporary Clinical Trials

SN - 1551-7144

M1 - 105908

ER -